Innovent's IBI363 Receives Second NMPA Breakthrough Therapy Designation For Immuno-resistant SqNSCLC
5/6 03:00
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced Wednesday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation to its first-in-class PD-1/IL-2a-bias bispecific antibody...